Tackling the key challenges for therapeutic oligonucleotide manufacture: cost, scale, and sustainability

In this wide-ranging interview David McCall, Senior Editor, BioInsights, and Ben Andrews, Senior Manager in Strategic External Development, GlaxoSmithKline, discuss the key challenges and opportunities for successful oligonucleotide manufacturing at scale, the merits and drawbacks of various synthesis options, and current efforts to mitigate the industry’s environmental impact.

Please enter your email to access content Read now